Lead party: ASP Isotopes Inc. (lead investor/buyer)
Coverage: Meridian Capital (investment and transaction tracker; data from Partner Researchers, editorially reviewed).
Target: PET Labs Pharmaceuticals Proprietary Limited (private company) · Sector: Healthcare, Pharmaceuticals · Countries of operation: South Africa
Transaction type: Investment · Asset class: Corporate Transactions · Strategy: Buyout · Instrument: Ordinary Shares (Equity), Options · Deal amount: US$2m · Equity stake: 0.51% · Implied EV: US$3.9m
Lead investor/buyer: ASP Isotopes Inc. · Investors/buyers: ASP Isotopes Inc. · Sellers: Nucleonics Imaging Proprietary Limited
Legal advisers: not identified in the source record.
Source: announced 31 October 2023. Original announcement: ir.aspisotopes.com.


